Hydrochloric Acid

Hydrochloric Acid

SCHEMBL3212988

CCCCCCCCCCCC[N+](C)(C)CCCCCCCCCCC(=O)O.[Cl-]

nearest known ligand 0.68

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA

The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR84 Q9NQS5 7/20 0.68
PPARG P37231 7/20 0.68
PPARD Q03181 7/20 0.68
PPARA Q07869 7/20 0.68
HDAC11 Q96DB2 5/20 0.68
TSHR P16473 4/20 0.68
PTPN1 P18031 3/20 0.68
ALDH1A1 P00352 2/20 0.68
TLR2 O60603 2/20 0.68
TDP1 Q9NUW8 2/20 0.68
FABP4 P15090 2/20 0.68
KMT2A Q03164 2/20 0.68
SLC22A6 Q4U2R8 1/20 0.68
SLC22A8 Q8TCC7 1/20 0.68
MEN1 O00255 1/20 0.68
ESR1 P03372 1/20 0.68
ALOX15 P16050 1/20 0.68
PDE4A P27815 1/20 0.68
PDE3A Q14432 1/20 0.68
HSD17B10 Q99714 1/20 0.68

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Stearic Acid SCHEMBL27477635 1.00 GPR84 (0.68) GPR84PPARGPPARDPPARAHDAC11
Didecyldimethylammonium SCHEMBL5028739 0.98 GPR84 (0.71) GPR84PPARGPPARDPPARAHDAC11
SCHEMBL18237024 0.98 GPR84 (0.71) GPR84PPARGPPARDPPARAHDAC11
Stearic Acid SCHEMBL11344274 0.98 GPR84 (0.71) GPR84PPARGPPARDPPARAHDAC11
Adipic Acid SCHEMBL8158150 0.98 GPR84 (0.71) GPR84PPARGPPARDPPARAHDAC11
SCHEMBL8332393 0.98 GPR84 (0.71) GPR84PPARGPPARDPPARAHDAC11
SCHEMBL5463837 0.98 GPR84 (0.71) GPR84PPARGPPARDPPARAHDAC11
Didecyldimethylammonium SCHEMBL381738 0.98 GPR84 (0.71) GPR84PPARGPPARDPPARAHDAC11
SCHEMBL8335621 0.98 GPR84 (0.71) GPR84PPARGPPARDPPARAHDAC11
SCHEMBL18237022 0.98 GPR84 (0.71) GPR84PPARGPPARDPPARAHDAC11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100160282-A1 NOVEL DIPHENYLAZETIDINONES, PROCESS FOR THEIR PREPARATION, MEDICAMENTS COMPRISING THESE COMPOUNDS AND THEIR USE SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2010-06-24 US disclosed
US-7674773-B2 Diphenylazetidinones, process for their preparation, medicaments comprising these compounds and their use SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2010-03-09 US disclosed
US-7576200-B2 Diphenylazetidinones, process for their preparation, medicaments comprising these compounds and their use SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2009-08-18 US disclosed
US-7488829-B2 Diphenylazetidinones, process for their preparation, medicaments comprising these compounds and their use SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2009-02-10 US disclosed
US-20080281092-A1 Novel diphenylazetidinones, process for their preparation, medicaments comprising these compounds and their use AVENTIS PHARMA DEUTSCHLAND GMBH 2008-11-13 US disclosed
US-20070208179-A1 Novel diphenylazetidinones, process for their preparation, medicaments comprising these compounds and their use AVENTIS PHARMA DEUTSCHLAND GMBH 2007-09-06 US disclosed
US-6992067-B2 Diphenylazetidinones, process for their preparation, medicaments comprising these compounds and their use AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2006-01-31 US disclosed
US-20050267038-A1 Novel diphenylazetidinones, process for their preparation, medicaments comprising these compounds and their use AVENTIS PHARMA DEUTSCHLAND GMBH 2005-12-01 US disclosed
CN-1217927-C Novel 1, 2-diphenzylazetidinones, method for producing the same, medicaments containing said compounds, and the use thereof for treating disorders of the lipid metabolism AVENTIS PHARMA GMBH (DE) 2005-09-07 CN disclosed
CN-1483021-A Novel 1, 2-diphenyl azetidinones, process for their preparation, medicaments containing them and their use in the treatment of disorders of lipid metabolism ���ĵ�˹ҩ��¹����޹�˾ 2004-03-17 CN disclosed
US-20020137689-A1 Novel diphenylazetidinones, process for their preparation, medicaments comprising these compounds and their use SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2002-09-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080281092-A1 Novel diphenylazetidinones, process for their preparation, medicaments comprising these compounds and their use QDPR, NDUFB6, NDUFB7 GPR84 3424/4885PPARG 618/4885PPARD 212/4885
US-20020137689-A1 Novel diphenylazetidinones, process for their preparation, medicaments comprising these compounds and their use QDPR, NDUFB7, NDUFB6 GPR84 3480/4885PPARG 703/4885PPARD 251/4885
US-20050267038-A1 Novel diphenylazetidinones, process for their preparation, medicaments comprising these compounds and their use QDPR, NDUFB6, NDUFB7 GPR84 3424/4885PPARG 618/4885PPARD 212/4885
US-20100160282-A1 NOVEL DIPHENYLAZETIDINONES, PROCESS FOR THEIR PREPARATION, MEDICAMENTS COMPRISING THESE COMPOUNDS AND THEIR USE QDPR, NDUFB6, NDUFB7 GPR84 3424/4885PPARG 618/4885PPARD 212/4885
US-20070208179-A1 Novel diphenylazetidinones, process for their preparation, medicaments comprising these compounds and their use QDPR, NDUFB6, NDUFB7 GPR84 3424/4885PPARG 618/4885PPARD 212/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.